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Abstract
Background: Hippocratea celastroides Kunth, commonly known as “cancerina”, is used in Mexican Traditional
Medicine for the treatment of gastric and intestinal infections, systemic and skin inflammation, injuries and
gastritis. The aim of this research was to assess the anti-Helicobacter pylori activities of hydro-ethanolic root-bark
extracts from Hippocratea celastroides Kunth in naturally infected dogs, after testing their acute and subacute
toxicities in mice.
Methods: To determine in vivo acute toxicity, a hydro-ethanolic extract was obtained and administered orally in
female and male Balb-C mice, at doses ranging from 2000 to 5000 mg/kg. For the subacute study, a hydro-ethanolic
extract was given to male and female Balb-C mice at doses ranging from 200 to 2000 mg/kg body weight.
The animals were observed daily over a period of 42 days for signs of toxicity. In the pre-clinical anti-Helicobacter spp.
assay, 60 dogs were included. Eighteen and 19 dogs for the experimental and control groups respectively, concluded
the study. The experimental treatment consisted of H. celastroides hydro-ethanolic extract and the control treatment
of amoxicillin-clarithromycin-omeprazole.
Results: Oral LD50 (lethal dose 50) values for hydro-ethanolic extract were indeterminable at the highest tested
doses. Under the subacute administration, neither mortality nor any sign of toxicity were observed when the
hydro-ethanolic extract was administered. There were no significant alterations in biochemical parameters. The
prevalence of Helicobacter spp. infection in dogs was 97.1 % for the experimental group and 100 % for the
control group. Effectiveness was of 33.3 and 55 % in the experimental and control group respectively. The oral
administration of H. celastroides was well-tolerated and safe.
Conclusion: The root-bark of H. celastroides produced no signs of toxicity, and manifested pharmacological
activity that indicated the possibility of an alternative treatment for H. pylori infection. Effectiveness is still low
so it is necessary to continue research.
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Background
Hippocratea celastroides Kunth, a shrub-like vine that is
widely distributed throughout Mexico, grows in tropical
deciduous forests [1]. Its popular names in Mexico
are “cancerina”, “barajilla”, “barajita”, “bejuco de piojo”,
“cucaracho”, “hierba del piojo”, “ixcate”, “ixcatecimarron”,
“izcate blanco”, “mata piojo”, “piojoso”, “quina” [2, 3]. In
the state of Mexico, H. celastroides is used as a purgative,
a stomach antiseptic, a general de-wormer and also an
acaricide [4–6]. In the state of Morelos, the infusion is
used for the treatment of gynecological conditions, and
topically for cuts and bruises, whereas the baked root-
bark is used to treat topical and internal inflammation,
as well as infections, injuries and gastritis [3, 7].
According to phytochemical investigations reported
for this species, alditol galactitol was identified from
the roots [8]. Celastroidine A (C50H74O5) was identi-
fied as a Diels–Alder adduct of a triterpene plus a
diterpene, whereas Celastroidine B (C40H60O4) was
identified as a dimer of a beyerane diterpene [9]. Tox-
icity and anti-feeding properties of Celastroidine A
and B were examined as a control against the stored
grain pest S. zeamays. Celastroidine A inhibited the
feeding of the insect 88.7 % with a mortality increase
of 2 %, whereas B showed 9.6 % anti-feeding inhibition
with a mortality of 5.2 % [2].
In our previous study, when acute ulcers were induced
in mice through oral administration with absolute
EtOH, H. celastroides MeOH root extract evidently
provided gastro-protective activity [10]. In this same
investigation, the topical anti-inflammatory action of
the extract using the ear acute edema mice model was
recorded. The root extract showed cytotoxic activity
against nasopharyngeal (KB) and breast (MCF-7) cancer
cell lines, but non-toxic selectivity towards a normal
fibroblast cell line (HFS-30). The MeOH extract exhibited
in vitro anti-H. pylori activity and registered a MIC
value of 7.8 μg/mL [10].
The discovery of Helicobacter pylori in human beings
and its relationship to gastritis, peptic ulcer disease,
gastric adenocarcinoma, and mucosa-associated lymphoid
tissue (MALT) lymphoma [11, 12], has encouraged
investigation of the incidence, clinical significance and
treatment of Helicobacter spp. infection in domestic
pets, specifically dogs. The presence of Helicobacter
spp. in gastric canine mucosa provokes mixed infections
caused by various Helicobacter species (Helicobacter
pylori, Helicobacter felis, Helicobacter bizzozeronii,
Helicobacter candidatus, Helicobacter heilmannii,
Helicobacter cynogastricum, and Helicobacter salomonis
[13–16]. In dogs, the above spiral-shaped bacteria are
found in the gastrointestinal tract. According to
numerous studies they are present in between 62.7
and a 100 % of healthy dogs and dogs with signs of
gastritis, including client-owned dogs and other dogs,
euthanized for various reasons [17–21]. H. felis has
been associated with active chronic gastritis and H.
bizzozeronnii with duodenal and gastric ulcers [22].
Naturally occurring Helicobacter, can also colonize
the intestinal crypts leading to lymphocytic enteritis
and canine inflammatory bowel disease, often asso-
ciated with diarrhea, gastro esophageal reflux and
vomiting [23, 24]. There is documented evidence that
domestic animals are a source of infection for human
beings [22]. The species that colonize the human gas-
tric mucosa are H. felis, H. salomonis, H. bizzozeronii
and Candidatus Helicobacter heilmannii [22, 25].
Helicobacter spp. transmission mechanisms are fecal-
oral and oral-oral. Different studies suggest that direct
contact with pets, and poor hygiene conditions,
including contaminated food and water, may be deter-
mining factors for transmission between humans and
animals [26–29]. Treatment prescribed to eradicate
Helicobacter spp. in dogs is the same current therapy
schema prescribed to eradicate Helicobacter pylori in
humans. Preferred treatment in Mexico, as well as in
other countries is represented by a triple therapy, which
includes an acid secretion inhibitor (omeprazole), in
combination with two antibiotics (amoxicillin and
clarithromycin) [30–34]. However, there is also a problem
of antimicrobial resistance, as well as easy re-infection or
recurrence for various reasons, situations that have
been published in several studies [26, 35, 36].
The frequent occurrence of gastric Helicobacter in
pets, the risk of it being transmitted to human beings
and its bacterial resistance have motivated this investi-
gation to determine the effectiveness, safety and tole-
rability of hydro-ethanolic Hippocratea celastroides root
extract to combat this bacterial infection. Firstly, we
evaluated the acute and subacute toxicological effects
of this plant extract on mice, and then we determined




Hippocratea celastroides Kunth (Hippocrateaceae) root-
barks were collected in June 2011 in Yautepec, Morelos,
Mexico. The plant was identified by Rolando Ramirez
from the Herbarium of CIB (Centro de Investigaciones
Biológicas) at the Universidad Autónoma del Estado de
Morelos (UAEM), where a botanical voucher No. 26447
was deposited for reference. Plant material was dried
under dark conditions for a period of two months. A
70 % hydro-ethanolic extract of Hippocratea celastroides
using the root barks was prepared by MIXIM Laboratories
(http://www.labmixim.com/espanol/historia.html), code
number 1901097. An HPTLC analysis of H. celastroides
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extract to detect the presence of alkaloids and triterpenes
was performed (Additional file 1).
In vivo toxicological evaluation
The rodents were obtained from the animal laboratory of
INSP (Instituto Nacional de Salud Pública), Cuernavaca,
Morelos, Mexico. Male and female Balb-C mice (18 ±
25 g) of 6–8 weeks were used. All animals were clinically
healthy and maintained under regular husbandry condi-
tions; 23 ± 2°, 12 h light dark cycle with ad libitum access
to water and standard rodent chow. In order to become
familiarized with environmental and handling conditions,
all animals were introduced to translucent animal cages
and handled daily for 1 week, prior to experimentation.
Acute toxicity
Rodents were separated into five groups; ten rodents in
each group, ten females and ten males. These comprised
the control group and four experimental groups, each of
which received different doses of the hydro-ethanolic
extract from H. celastroides (2000, 3000, 4000 and
5000 mg/kg of body weight with an oral single dose
diluted in 0.9 % saline solution). The control group
received 0.9 % saline solution at an equivalent volume.
The rodents were deprived of food and water 2 h prior
to administration of the extracts. The solutions were
administered using a metallic cannula. Observations
were made and systematically recorded after 1, 2 and 4 h
of extract administration. Visual observations included
skin changes, modifications in respiratory patterns,
motility, diarrhea, behavioral pattern, convulsions and
death. Animal mortality and survival were recorded
daily for 14 days subsequent to extract administration,
after which they were sacrificed by decapitation.
Sub-acute toxicity
For the assay, four groups (ten rodents each, five female
and five male) to test doses of 200, 1000, 2000 mg/kg
and the control group were formed in a similar way. Six
weeks old rodents were deprived of food but not of
water 2 h prior the administration of the tested sub-
stances. A daily dose of hydro-ethanolic extract from H.
celastroides was administered for 28 days to each group.
The hydro-ethanolic extract solution was prepared every
day by dissolving the crude extract in 0.9 % saline solu-
tion and then administered using a metallic cannula.
The control group was given only the vehicle using the
same route and volume. All rodents were observed daily,
as well as 14 days after having finished the extract
administration to detect signs of toxicity or behavioral
alterations during the experimental period. On day 42,
all rodents were sacrificed by decapitation, and the
organs (brain, liver, kidney, heart, pancreas, stomach,
lungs, and intestine) were collected for macroscopic
observation. The serum aspartate transaminase (AST),
as well as urea and creatinine were determined.
Preclinical anti-Helicobacter spp. assay
Subjects
In this study, we included 60 adult dogs, 6–32 kg.
The controlled preclinical trial was conducted at the
APAC (Asociación Protectora de Animales Philip Kahan)
shelter for dogs, and at the “Animal’s” Veterinary Hospital.
Animals included symptomatic and asymptomatic dogs
of both sexes. Excluded animals were those with cardiac
hepatic or renal illness, pregnant, with additional infec-
tions, or taking ulcerogenic antibiotic or anti-secretory
treatments. The treatments were assigned according to
the section assigned in the dog shelter; region A was
assigned for experimental treatment and section B for
the control group. Thirty five dogs were enrolled in
the experimental group and 25 dogs in the control
group, 16 and 6 dogs in the experimental and control
groups respectively were excluded because they had
been given up for adoption, or the owners decided to
suspend the anti-Helicobacter treatment. None of the
dogs involved suffered adverse effects. At the end, the
experimental group included only 18 dogs (one dog
was negative to Helicobacter infection) and the control
group included only 19 dogs.
Study intervention
The experimental group received 500 mg of the hydro-
ethanolic extract from Hippocratea celastroides root in
capsules of 500 mg every 12 h for a period of 12 weeks,
and the control group received the triple schema of
500 mg amoxicillin, 500 mg clarithromycin and 20 mg
omeprazole every 12 h for a period of 7 days.
Study protocol
To perform the upper digestive endoscopy, the anesthetic
medication consisting of a mixture of 1 mg/kg Xilacine
and 7 mg/kg Zoletil 100 (Tiletamine/zolazepam), was
injected intravenously to all dogs involved. The same
gastroenterologist, using an Olympus GIF-130 gastro-
scope, performed all the endoscopies. The first endoscopy
for each dog was performed prior to initial treatment in
order to make the Helicobacter spp. infection diagnosis,
and a second endoscopy was performed at the end of
the assigned treatment to verify eradication. The samples
collected in both endoscopies were from fundus, antrum
and pre-pyloric regions. One sample from each stomach
region was immediately immersed in a 10 % formol
solution in order to implement histopathologic exams
by staining with haematoxylin-eosin and giemsa. The
dogs in the experimental group were observed weekly
throughout the research period and daily for the control
group, for the purpose of checking possible adverse
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effects. One day following conclusion of therapy, the
animals were submitted to a new upper digestive endos-
copy to take gastric mucosal biopsies from fundus, antrum
and pre-pyloric regions, in order to verify bacterial eradi-
cation. To investigate the safety of H. celastroides extract
and the triple schema, blood samples were obtained prior
to initiation of treatment, and again when the second
endoscopy was performed.
Outcome measures
The bacillary presence or absence of Helicobacter spp
was confirmed at the end of the assigned treatment with
the stain haematoxylin-eosin and giemsa. Absence of
bacillus in samples from the three regions studied was
considered as signifying eradication. Side effects were
registered weekly to assay tolerability by means of a table
assigned to each dog for internal use at the veterinary
hospital. Safety was determined by following the plasma
biochemical levels of urea, creatinine, ALT and AST,
prior to treatment initiation and at the end of the
assigned treatment.
Statistical analysis
In the sub-acute toxicity study, body weight data were
expressed as the mean ± standard error of the mean
(S.E.M.). All values with normal distribution and homo-
geneity among variances were analyzed by one way
ANOVA followed by Dunnett’s multiple comparison
tests. Analysis of effectiveness was performed using
chi-square test. Serum values of biochemical parameters
were analyzed by using t-test; the results are expressed as
mean ± standard deviation of the mean. The Graph Pad
Prism Statistics Software program was used. A probability
level of less than 0.05 was considered significant.
Results
In the toxicity assays, the oral LD50 values for hydro-
ethanolic extract were not determined as none of the
rodents exhibited any toxicological symptoms such as
diarrhea, skin changes, alterations in respiration, moti-
lity, and behavioral patterns, convulsions or death for up
to the highest assayed dose (5000 mg/kg). LD50 values
higher than 5000 mg/kg are considered non-toxic
according to the GHS (Globally Harmonized System).
In the sub-acute toxicity treatment using the hydro-
ethanolic extract, the differences in weight gain at day
28 between control and experimental rodents, both male
and female, showed no statistical differences (Fig. 1).
Fig. 1 Effect of hydro-ethanolic root-bark extract of Hippocratea celastroides on weight gain at 200, 1000, and 2000 mg/kg body weight administered
daily for 28 days. Foot note.- (Mean ± SE) n = 10, p < 0.05 Dunnett’s. Non-significant changes were observed compared to control
Table 1 Blood chemistry values with the hydro-ethanolic
extract of H. celastroides in the subacute toxicity assay
Control 200 mg/kg 1000 mg/kg 2000 mg/kg
AST (U/L) 41.07 ± 4.1* 13.62 ± 3.6 31.5 ± 3.6* 38.28 ± 5.9*
Urea 23.1 ± 0.80* 27.77 ± 1.13 26.9 ± 1.38 23.75 ± 0.77*
Creatinine 0.2 ± 0.03* 0.26 ± 0.03* 0.21 ± 0.01* 0.25 ± 0.03*
n = 10 (for control and experimental groups). AST aspartate
aminotransferase. *(P < 0.05)
Table 2 Proportion of gastric mucosal lesions in dogs at
baseline (experimental and control groups)
Histopathological diagnosis f rf
Chronic superficial gastritis 25 41.6
Chronic follicular gastritis 18 30
Chronic chemical gastritis 12 20
Chronic atrophic corporal gastritis 2 3.3
Chronic atrophic multifocal gastritis 2 3.3
Normal gastric mucosa 1 1.6
n = 60, f absolute frequency, rf relative frequency (%)
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No morbidity or mortality was observed during the
first 28 days, or in the following 14. Blood chemical
analyses were performed in order to evaluate any
toxic effects on the kidney (urea and creatinine) and
liver (AST) function. Table 1 shows the results of serum
parameters for animals to which H. celastroides was
administered. Regarding AST levels, the extract adminis-
tered at a dose of 2000 mg/kg body weight over a 28 days
period showed no significant difference when compared
to the control group. Although there was a significant
Fig. 2 Lesions of gastric mucosa of dogs in the pre-clinical evaluation of anti-Helicobacter spp. activity of H. celastroides. Foot note.- Presence of
Helicobacter spp. intraglandular (a); mononuclear inflammatory infiltrates and edema in the chronic superficial gastritis (b); foveolar hyperplasia in
the chronic chemical gastritis (c); intestinal metaplasia in the chronic atrophic gastritis (d); presence de lymphoid follicle in the chronic follicular
gastritis (e and f), indicated by arrows
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difference at a dose of 200 mg/kg, the value fell within the
normal range and had no clinical relevance. A significant
difference was detected between the doses of 200 and
1000 mg/kg regarding urea level; although, these values
also fell within the normal ranges [37]. Creatinine values
also fell within the normal range, indicating that at the
end of the treatment both liver and kidney were healthy.
The prevalence of Helicobacter spp. infection in the
canine population studied was 97.1 and 100 % for the
experimental and control groups respectively, referring
to the initial number of dogs included in the study
(35 and 25 in the experimental and control groups
respectively). Only one dog was healthy. The classifi-
cation of lesions was made according to the Updated
Sydney Classification System. Mean lesions reported,
prior to the treatment assigned for both groups, in-
cluded chronic superficial gastritis, chronic follicular
gastritis, chronic chemical gastritis, corporal chronic
atrophic gastritis, and multifocal chronic atrophic
gastritis (Table 2). Figure 2 shows the presence of
Helicobacter spp. intraglandular (A); it is also possible
to observe the mononuclear inflammatory infiltrates
and edema in the chronic superficial gastritis (B);
foveolar hyperplasia in the chronic chemical gastritis
(C); intestinal metaplasia in the chronic atrophic
gastritis (D); and the presence of lymphoid follicle in
the chronic follicular gastritis (E and F). Mean clinical
signs found in symptomatic dogs included diarrhea,
vomiting, loss of weight and halitosis; all of which
were eliminated during the first week of both treat-
ments. The analysis for effectiveness showed 33.3 and
55 % eradication for the experimental (H. celastroides
extract) and control group (amoxicillin-clarithromycin-
omeprazole) respectively, without any significant diffe-
rence between the two groups (Table 3). Regarding the
overall tolerability of interventions, only 6 dogs in the
control group experienced mild effects (diarrhea), so it
was not necessary to exclude them from the study. The
therapeutic safety (determined through urea, creatinine,
AST, and ALT values) was 84.2 and 80 % in the experi-
mental and control groups respectively, without signifi-
cant differences (Table 4). Figure 3 shows the values
for urea, creatinine, AST and ALT with non-significant
difference in each media between both groups. The
normal ranges for biochemical parameters in the litera-
ture reported for dogs are: AST 12–60 U/L [38, 39], ALT
10–100 U/L [39, 40], urea 21–60 mg/dL [41] and creatin-
ine 0.5–1.6 mg/dl [41]. According to these data, our re-
sults show values out of the normal range in three dogs
from the experimental group and four dogs from the
control group; however, no clinical significance was
evident, so the dogs did not require additional treat-
ment and were observed for future alterations.
Discussion
Considering toxicity parameters, no rodent death was
recorded in either control or treatment groups during
acute toxicity. We can thus conclude that H. celastroides
root-bark is non-toxic with regard to the threshold for
toxic substances (6 g/kg) stipulated by the GHS (Global
Harmonized System). H. celastroides can be categorized
as a non-observed-adverse-level (NOAEL) crude drug
that acts safely under current normal usage [42, 43].
With respect to the assay of subacute toxicity, the
hydro-ethanolic extract of H. celastroides root-bark
presented no evidence of toxicity. The level of AST with
the maximal dose of the plant extract (2000 mg/kg) had
a mean of 38.28 ± 5.91 U/l, a low value when compared
to other toxicological studies that indicate hepatic dam-
age, for example the administration of CCl4, a potent
chemical hepatotoxic that causes hepatocellular damage
with markedly elevated activities of serum enzymes
(mean 968.58 ± 439.52 U/L; >2000 U/L) [44, 45]. Some
studies in the literature have described how pre-
induction with 50 % (v/v) ethanol provoked a significant
elevation of serum AST levels (902.8 ± 16.7) [45]. In
relation to the kidney function tests for creatinine and
urea [46], the results indicate that the rodents’ kidneys
were not affected with the highest administered dose
(2000 mg/kg). There were significant differences between
the doses of 200 and 1000 mg/kg in terms of urea level;
nevertheless, these values also fell within normal ranges
[37]. The prevalence of Helicobacter spp. infection in dogs
that we reported (98.1–100 %) is similar to that reported
for other countries; 95–100 % Finland [18], 87–100 %
USA [47], 61–99 % Germany [17], 85.1 % Poland [21]
and 78.4–82.3 % in Korea [20]. Taking care of the
zoonotic potential, this fact indicates the importance
of the health problem for both humans and pets. In
relation to the mean lesions found in the gastric mucosa
Table 3 Helicobacter spp. eradication using H. celastroides extract
and triple schema (amoxicillin-clarithromycin-omeprazole)
f (rf) Chi2 (P value)
H. celastroides (n = 18) 6 (33.3)
Triple schema (n = 20) 11 (55) 0.0899
f absolute frequency, rf relative frequency (%)
(P < 0.05)
Table 4 Safety therapeutic of H. celastroides and triple schema
treatments
f (rf) Chi2 (P value)
H. celastroides (n = 19) 16 (84.2)
Triple schema (n = 20) 16 (80) 0.3660
f absolute frequency, rf relative frequency (%)
Absence of any urea, creatinine, aspartate transaminase and alanine
transaminase abnormal values
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of the dogs examined, our results concur with other
studies that report the frequent occurrence of gastritis
in dogs, mainly superficial gastritis, chronic active
gastritis and lymphoid follicles [17, 19, 48, 49]. When
compared to human studies, the lesions found in H. pylori
infection are similar, and establish that chronic inflam-
mation by H. pylori causes superficial gastritis that
may evolve to gastric atrophy and intestinal metaplasia
in approximately half of patients, especially in patients
suffering from severe inflammation [50, 51].
The weight of the dogs included in the study ranged
between 6 and 32 kg, so the dose of H. celastroides
extract administrated to the dogs ranged from 93.5 to
500 mg/kg in weight. The dose was determined accord-
ing to the amount of plant used traditionally in humans
(170 mg/kg), and taking as reference the doses of other
plant extracts or plant preparation studies that were
assayed for anti-Helicobacter activity such as: Amu-ru7 a
Mongolian folk medicine composed from Rhei rhizome,
Hedychium spicatum, Radix auklandiae, Terminalia
chebula, Cape Jasmine fruit, Piper longum and Calcite
(200 and 800 mg/kg) [52], Calophyllum brasiliense in
Brazil (100 and 200 mg/kg) [53], and the Thai plant
Boesenbergia (100 mg/kg) [54].
Results obtained from the experimental group indi-
cated 33.3 % effectiveness, whereas effectiveness in the
control group using the currently accepted standard
treatment was 55 %. However, our current results
showed no statistical difference in effectiveness between
both groups. These figures do indicate how difficult is to
eradicate this infection under the most controlled sani-
tized conditions, further indicating the importance of
continued research for its eradication among both dogs
and owners.
In comparison to effectiveness of the triple schema
with amoxicillin-clarithromycin-omeprazole, we expected
to obtain a similar proportion of effectiveness as that
reported for humans in Mexican populations; however,
our values were lower than that for assays among humans,
which have shown a proportion of effectiveness of
65.5–89.7 % [33, 55, 56]. It may be that H. celastroides
will demonstrate greater effectiveness. We propose a
second pre-clinical assay with three groups of study, a
first group with a higher dose of H. celastroides extract
plus omeprazole, a second group with a lower dose plus
omeprazole, and the third group with the standard triple
schema plus H. celastroides. Taking into account the
results obtained with Nigella sativa, which was admi-
nistered to humans at doses of 1, 2 and 3 g in combi-
nation with omeprazole, showing frequencies of H. pylori
eradication of 47.6, 66.7 and 47.8 % respectively, we
expect the addition of omeprazole to improve effective-
ness [57]. Likewise, in order to improve the eradication
effect of the triple schema, H. celastroides will be added,
anticipating similar results to those from the clinical
assay, where the addition of cranberry juice improved the
rate of H. pylori eradication from 80.0 % (omeprazole,
amoxicillin and clarithromycin) to 95.2 % (omeprazole,
Fig. 3 Blood chemistry values with the hydro-ethanolic extract of H. celastroides and triple schema in the therapeutic safety analysis.
Foot note.- a ALT = alanine aminotransfesare, AST = aspartate aminotransferase. b Urea, and Creat = creatinine. Values are expressed as
mean ± SE, n = 10. p < 0.05 T test. Non-significant difference was observed between both groups
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amoxicillin, clarithromycin and cranberry juice) [58].
Some studies indicate that certain proton pump inhi-
bitors (omeprazole), not only have an inhibitory effect on
acid secretion, but also exert antibacterial activity in vitro,
which is selective to H. pylori [59]. This antimicrobial
activity is common to all benzimidazoles and absent in
other anti-secretory drugs such as H2-antagonists [60, 61].
The safe therapeutic benefits of H. celastroides extract
were demonstrated with the absence of renal and hepatic
damage. There were 3 dogs with altered results in the
H. celastroides group; however, levels of urea and
creatinine had no clinical significance.
This is the first report indicating the prevalence of
Helicobacter spp. infection in a Mexican canine popu-
lation, and the first investigation to assay a medicinal
plant in a canine population naturally infected with
Helicobacter spp.
Conclusions
H. celastroides is a non-toxic plant, so its use internally
complies with GHS stipulations. The prevalence of
dogs infected with H. pylori is very high, and zoonotic
risk increases the need to treat this condition. The values
indicating eradication of Helicobacter spp in the con-
trolled preclinical trial of H. celastroides hydro-ethanolic
extract and triple schema of amoxicillin-clarithromycin-
omeprazole in naturally infected Mexican dogs showed
no statistical difference. Both treatments were safe and
well tolerated, when taken orally.
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